



BioMarker
STRATEGIES

News Release

Contact:

Jerry Parrott, President & CEO

301-938-4043 Mobile

jparrott@biomarkerstrategies.com

FOR IMMEDIATE RELEASE

January 7, 2016

BioMarker Strategies Announces Issuance of Key Patents in the United States, Europe, Australia and Hong Kong

*Recently issued patents for the Company's SnapPath® Cancer Diagnostic System:
"Improved Methods and Devices for Cellular Analysis"*

Rockville, MD – January 7, 2016 – BioMarker Strategies, LLC, today announced that patents covering its core technology have been granted in the United States, Europe, Australia and Hong Kong.

“We developed the SnapPath® Cancer Diagnostics System to enable predictive tests to guide targeted drug development and treatment selection for patients with solid tumor cancers,” said Jerry Parrott, President and CEO, BioMarker Strategies. “The mission of our company is to make personalized medicine more of a reality for these patients. The issued patents we are announcing today recognize our invention and encourage us to work even harder to achieve this critically important mission.”

BioMarker Strategies was founded to address a significant drug development and medical need: Available biomarker tests for solid tumors primarily rely on dead, fixed tissue samples. These tests can identify mutations and suggest general therapeutic approach, but are not useful in understanding acquired resistance and do not accurately and dependably predict individual response.

SnapPath® is the only diagnostics system able to generate purified populations of live solid tumor cells from fresh, unfixed samples in a rapid and standardized manner. SnapPath® makes possible a new class of biomarker tests called PathMAP® Functional Signaling Profiles, which help identify and understand mechanisms of acquired resistance. These tests are highly predictive of individual response because they are based on the dynamic, predictive signaling information available only from live cells.

NEWS RELEASE

At the beginning of 2014, Frost & Sullivan recognized BioMarker Strategies for its “ground-breaking innovation” in pioneering the development and validation of SnapPath® by presenting the Company with the Frost & Sullivan Technology Innovation Leadership Award in Cancer Diagnostics. A Frost & Sullivan press release announcing the award on January 13, 2014 said, “The BioMarker Strategies SnapPath® platform is compatible with multiple solid tumor sample types and the system ensures the health of the live tumor cells, allowing them to interact with stimulants and suppressors to generate functional information. This represents a milestone in cancer research, offering opportunities for the development of new drugs, predictive diagnostics, and research services. The utilization of these technologies may ultimately lead to a paradigm shift in investigational design as well as data management and processing.”

Patents Issued to BioMarker Strategies during 2015 for the SnapPath® Cancer Diagnostics System: “Improved Methods and Devices for Cellular Analysis”

<u>Country/Region</u>	<u>Patent #</u>	<u>Issue Date</u>	<u>Expiration</u>
United States	US9,121,801	September 1, 2015	December 28,2030
Europe	EP2210080*	January 28, 2015*	October 24, 2028*
Australia	AU2008317329	January 15, 2015	October 24, 2028
Hong Kong	HK1145878	August 14, 2015	October 24, 2028

*European patent validated in United Kingdom, France, Germany, Italy, Spain, Belgium, The Netherlands, Poland, Sweden and Switzerland

About BioMarker Strategies

BioMarker Strategies has developed SnapPath®, the only cancer diagnostics system that automates and standardizes functional *ex vivo* profiling of live solid tumor cells from fresh biopsies or other fresh, unfixed samples such as xenografts or tumorgrafts. SnapPath® can help guide cancer drug development and treatment selection. The Company’s PathMAP® Functional Signaling Profiles, created using the SnapPath® system, represent a new class of biomarker tests that are highly predictive of individual response to targeted treatment. PathMAP® Melanoma is currently in development as a companion diagnostic under a National Cancer Institute SBIR Phase II contract, the ultimate goal of which is to prepare for a clinical trial of PathMAP® Melanoma under a Phase IIB NCI contract. For more information about BioMarker Strategies, please see www.biomarkerstrategies.com.

Forward-Looking Statements

The information in this press release includes our projections and other forward-looking statements regarding future events. In some cases, forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “projects,” “estimates,” “predicts,” “potential,” “continue”, etc. These statements are not guarantees of future performance or achievement and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is projected here.

###